Nanoparticle-Based Drug Delivery and Associated Toxicological Considerations
Nanoparticle-based drug delivery systems have transformed the pharmaceutical landscape by enabling targeted, controlled, and efficient transport of therapeutic agents. However, the unique physicochemical properties of nanoparticles—such as high surface area, reactivity, and cellular penetration—also introduce distinct toxicological challenges that must be addressed during IND-enabling studies.
The biocompatibility, biodistribution, and clearance of nanoparticles depend on their size, charge, surface modifications, and material composition. Unlike conventional small molecules, nanoparticles may accumulate in the liver, spleen, and lymphatic tissues due to uptake by the mononuclear phagocyte system. Some particles cross biological barriers, such as the blood–brain barrier, leading to unanticipated tissue exposure. Surface coatings, such as PEGylation or ligand conjugation, alter immune recognition and circulation time but may themselves induce immune reactions or complement activation.
Nanotoxicology studies must evaluate both the core material and any surface modifications. Standard endpoints include clinical pathology, organ weights, histopathology, and evaluation of oxidative stress markers. Additional studies may include electron microscopy for cellular localization, cytokine profiling to assess immunogenicity, and toxicokinetics to understand tissue accumulation and clearance kinetics.
Toxicological assessment of nanoparticles also considers potential impurities, manufacturing variability, and interactions with biological macromolecules. Regulatory agencies have issued guidance specific to nanomaterials, and developers must demonstrate that nanoparticle formulations meet both safety and efficacy standards comparable to traditional drug products.
Incorporating nanotoxicology into IND-enabling programs ensures that nanoparticle-based therapies are not only effective but also meet rigorous safety standards for first-in-human trials.